These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease. Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038 [TBL] [Abstract][Full Text] [Related]
3. Increased rectal nitric oxide in children with active inflammatory bowel disease. Ljung T; Beijer E; Herulf M; Weitzberg E; Lundberg JO; Finkel Y; Hellström PM J Pediatr Gastroenterol Nutr; 2002 Mar; 34(3):302-6. PubMed ID: 11964958 [TBL] [Abstract][Full Text] [Related]
4. Rectal potential differences in irritable bowel syndrome and in inflammatory bowel diseases in man. Pienkowski P; Fioramonti J; Frexinos J J Intern Med; 1989 Dec; 226(6):423-7. PubMed ID: 2489227 [TBL] [Abstract][Full Text] [Related]
5. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Kristjánsson G; Venge P; Wanders A; Lööf L; Hällgren R Gut; 2004 Dec; 53(12):1806-12. PubMed ID: 15542519 [TBL] [Abstract][Full Text] [Related]
6. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912 [TBL] [Abstract][Full Text] [Related]
7. Differentiation Between Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study. Bosch S; van Gaal N; Zuurbier RP; Covington JA; Wicaksono AN; Biezeveld MH; Benninga MA; Mulder CJ; de Boer NKH; de Meij TGJ Inflamm Bowel Dis; 2018 Oct; 24(11):2468-2475. PubMed ID: 29788410 [TBL] [Abstract][Full Text] [Related]
8. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165 [TBL] [Abstract][Full Text] [Related]
9. Increased luminal nitric oxide in inflammatory bowel disease as shown with a novel minimally invasive method. Herulf M; Ljung T; Hellström PM; Weitzberg E; Lundberg JO Scand J Gastroenterol; 1998 Feb; 33(2):164-9. PubMed ID: 9517527 [TBL] [Abstract][Full Text] [Related]
10. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327 [TBL] [Abstract][Full Text] [Related]
11. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders. Ljung T; Lundberg S; Varsanyi M; Johansson C; Schmidt PT; Herulf M; Lundberg JO; Hellstrom PM World J Gastroenterol; 2006 Jun; 12(21):3386-92. PubMed ID: 16733856 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners. Abdalla MI; Sandler RS; Kappelman MD; Martin CF; Chen W; Anton K; Long MD Inflamm Bowel Dis; 2017 Feb; 23(2):325-331. PubMed ID: 28092305 [TBL] [Abstract][Full Text] [Related]
13. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Lettesjö H; Hansson T; Peterson C; Ung KA; Ringström G; Abrahamsson H; Simrén M Scand J Gastroenterol; 2006 Jan; 41(1):54-9. PubMed ID: 16373277 [TBL] [Abstract][Full Text] [Related]
14. (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. Hagan M; Hayee BH; Rodriguez-Mateos A Molecules; 2021 Mar; 26(7):. PubMed ID: 33805938 [TBL] [Abstract][Full Text] [Related]
15. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223 [TBL] [Abstract][Full Text] [Related]
16. Rectal nitric oxide assessment in children with Crohn disease and ulcerative colitis. Indicator of ileocaecal and colorectal affection. Ljung T; Herulf M; Beijer E; Jacobsson H; Lundberg J; Finkel Y; Hellström PM Scand J Gastroenterol; 2001 Oct; 36(10):1073-6. PubMed ID: 11589381 [TBL] [Abstract][Full Text] [Related]
17. Relationship between fecal lactoferrin and inflammatory bowel disease. Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860 [TBL] [Abstract][Full Text] [Related]
18. Stimulation of the nitric oxide-guanosine 3', 5'-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome. Fritz E; Hammer J; Schmidt B; Eherer AJ; Hammer HF Am J Gastroenterol; 2003 Oct; 98(10):2253-60. PubMed ID: 14572576 [TBL] [Abstract][Full Text] [Related]
20. The central role of psychopathology and its association with disease severity in inflammatory bowel disease and irritable bowel syndrome. Piacentino D; Cesarini M; Badiali D; Pallotta N; Biondi M; Corazziari ES Riv Psichiatr; 2019; 54(2):75-83. PubMed ID: 30985832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]